Similar articles

• [Chemoradiation for pancreatic adenocarcinoma].

  Flandin I, Mornex F, Claude L, Kubas A, Khodri M, Wautot V, Mazeron R, Partensky C. Flandin I, et al. Cancer Radiother. 2004 Nov;8 Suppl 1:S80-7. Cancer Radiother. 2004. PMID: 15679252 Review. French.
• Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma.

  Brown ZJ, Cloyd JM. Brown ZJ, et al. J Surg Oncol. 2021 May;123(6):1432-1440. doi: 10.1002/jso.26384. J Surg Oncol. 2021. PMID: 33831253 Review.
• Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer.

  Joensuu TK, Kiviluoto T, Kärkkäinen P, Vento P, Kivisaari L, Tenhunen M, Westberg R, Elomaa I. Joensuu TK, et al. Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):444-52. doi: 10.1016/j.ijrobp.2004.03.026. Int J Radiat Oncol Biol Phys. 2004. PMID: 15380578 Clinical Trial.
• [Pancreatic carcinoma--overcome technically but not oncologically].

  Herfarth Ch. Herfarth Ch. Chirurg. 2003 Mar;74(3):163-4. doi: 10.1007/s00104-003-0638-2. Chirurg. 2003. PMID: 12722765 German. No abstract available.
• [Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].

  Barhoumi M, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L, Chauffert B. Barhoumi M, et al. Cancer Radiother. 2011 Jun;15(3):182-91. doi: 10.1016/j.canrad.2010.10.001. Epub 2011 Feb 10. Cancer Radiother. 2011. PMID: 21315644 Clinical Trial. French.